<DOC>
	<DOCNO>NCT02372240</DOCNO>
	<brief_summary>This phase 1/2 single arm study determine safety efficacy VLX1570 IV infusion administer low dose dexamethasone patient relapse relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>A Study VLX1570 Dexamethasone Myeloma Patients</brief_title>
	<detailed_description>This phase 1/2 , open label study determine safety efficacy VLX1570 intravenous ( IV ) infusion administer low dose dexamethasone day 1 , 2 , 8 , 9 , 15 , 16 28-day cycle patient confirm diagnosis multiple myeloma relapse relapsed refractory disease ( RRMM ) . The phase 1 trial design follow Initial Accelerated Titration design follow traditional `` 3+3 '' cohort design establish maximum tolerate dose ( MTD ) recommend phase 2 dose ( RPTD ) phase 2 portion study . It anticipate patient receive 6 treatment cycle . In absence unacceptable toxicity disease progression , patient option continue treatment beyond 6 cycle , investigator determines patient may benefit .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Diagnosis relapse relapsed refractory multiple myeloma follow least 2 prior therapy must include least one immunomodulatory drug ( e.g. , thalidomide , lenalidomide pomalidomide ) one proteasome inhibitor ( e.g. , bortezomib carfilzomib ) . Patients must candidate regimen know provide clinical benefit . 2 . Measurable disease define 1 following : Serum monoclonal protein ≥ 0.5 g/dL Urine monoclonal protein &gt; 200 mg/24 hour Serum immunoglobulin free light chain &gt; 10 mg/dL AND abnormal kappa/lambda ratio ( reference 0.261.65 ) 3 . Estimated glomerular filtration rate ( GFR ) ≥30 mL/min assess CKDepi , MDRD CockcroftGault Equation 4 . Age ≥18 year . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . 6 . Females childbearing potential* must negative pregnancy test . 7 . Males females childbearing potential* must agree use effective contraception ( e.g. , oral contraceptive , IUCD , barrier method contraception conjunction spermicidal jelly ) abstinence study 30 day last dose . 8 . Absolute neutrophil count ( ANC ) ≥1.0 x 109 /L , hemoglobin ≥8 g/dL , platelet count ≥ 75 x 109/L . 9 . Adequate hepatic function , bilirubin &lt; 1.5 x ULN , AST ALT &lt; 2.5 x ULN . 10 . Patient willing central venous catheter drug administration . 1 . Any concurrent treatment would compromise study include limit : Planned concurrent treatment multiple myeloma bisphosphonates Ongoing corticosteroid indication multiple myeloma allow long dose exceed 10 mg prednisone per day equivalent Persisting effect previous ongoing treatment ≥ grade 1 might compromise delivery study treatment assessment adverse event ( except alopecia neuropathy ≤ grade 2 without pain ) 2 . Any cytotoxic biologic therapy le 2 week prior initiation therapy . 3 . Pregnant breast feeding female . 4 . Uncontrolled hypertension diabetes . 5 . Known active hepatitis B C infection HIV infection . 6 . Significant cardiovascular disease NYHA Class III IV symptom , hypertrophic cardiomegaly , restrictive cardiomegaly , myocardial infarction within 6 month prior enrollment , unstable angina , unstable arrhythmia . 7 . QTc interval &gt; 460 msec ( male ) &gt; 470 msec ( female ) ; repeat demonstration QTc interval &gt; 450 msec . 8 . A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) . 9 . The use concomitant medication prolong QT/QTc interval . 10 . Uncontrolled intercurrent illness include limited psychiatric illness/social situation , opinion Investigator , would compromise compliance study requirement put patient unacceptable risk . 11 . Active infection require systemic treatment within one week prior first dose . 12 . Major surgery within 1 month prior enrollment . 13 . Use investigational agent within last 28 day . For class investigational agent know prolonged toxicity washout time may decrease 14 day agreement Medical Monitor . 14 . History malignancy ( apart basal cell carcinoma skin , situ cervix carcinoma ) except patient free symptom without active therapy least 2 year . 15 . Known intolerance steroid H1/H2antagonists . 16 . Serum calcium ( correct albumin ) level ULN range ( treatment hypercalcemia allow subject may enroll hypercalcemia return normal standard treatment ) . 17 . Diagnosed plasma cell leukemia , POEMS syndrome amyloidosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>